Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders.

Nature communications - 25 May 2023

Katagiri Takenobu, Tsukamoto Sho, Kuratani Mai, Tsuji Shinnosuke, Nakamura Kensuke, Ohte Satoshi, Kawaguchi Yoshiro, Takaishi Kiyosumi

Abstract excerpt

Mutations in activin receptor-like kinase 2 (ALK2) can cause the pathological osteogenic signaling seen in some patients with fibrodysplasia ossificans progressiva and other conditions such as diffuse intrinsic pontine glioma. Here, we report that intracellular domain of wild-type ALK2 readily dimerizes in response to BMP7 binding to drive osteogenic signaling. This osteogenic signaling is pathologically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activin Receptors, Type I
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dimerization

Share to Mutation

Share to Myositis Ossificans

Share to Ossification, Heterotopic

Share to Osteogenesis

Source

Open in PubMed Open full text

Identifiers

PMID: 37231012
DOI: 10.1038/s41467-023-38746-5
PMCID: PMC10212922

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders.PMID 37231012Read ↗

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.Semantic proximity Read ↗

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro/adipogenic progenitors in fibrodysplasia ossificans progressiva miceSemantic proximity Read ↗

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.Semantic proximity Read ↗

Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Constitutively Active ALK2 Receptor Mutants Require Type II Receptor CooperationSemantic proximity Read ↗

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.Semantic proximity Read ↗

A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.Semantic proximity Read ↗

Recent Advances in ALK2 InhibitorsSemantic proximity Read ↗

Crystal structures of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10Semantic proximity Read ↗

Structural consequences of BMPR2 kinase domain mutations causing pulmonary arterial hypertensionSemantic proximity Read ↗

Recent progress in drug development for fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.